<DOC>
	<DOCNO>NCT02576639</DOCNO>
	<brief_summary>The study determine safety CNP520 healthy elderly 3 month . Data relevant Pharmacokinetic/Pharmacodynamic modeling obtain order define target dose subsequent efficacy study .</brief_summary>
	<brief_title>Dose-ranging Safety Tolerability Study Subjects ≥60 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key Healthy status Body weight : ≥45kg BMI : 1834 kg/m2 Key History presence clinically significant disease major system organ class . Heavy smoker status History /presence clinically significant neurological psychiatric disorder Any medical condition might lead associate cognitive deficit History presence severely impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alzheimer 's Disease ,</keyword>
	<keyword>Amyloid Beta ,</keyword>
	<keyword>cerebrospinal fluid ,</keyword>
	<keyword>beta secretase</keyword>
</DOC>